Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Medical Device PIC

Johnson & Johnson MedTech and CED Medical Sign Third Strategic Cooperation Agreement to Expand Neurointerventional Partnership Behind Qiangyida Stent

Fineline Cube Sep 1, 2026
Company Deals PIC

WestGene and CREATE Sign License Deal to Co‑Develop In Vivo CAR‑T Therapies

Fineline Cube Aug 31, 2026
Company Deals PIC

Simnova Closes nearly RMB 400 Million Series B to Advance CAR‑NK Candidate SNC103

Fineline Cube Aug 31, 2026
Company Deals PIC

Leaderna Therapeutics Closes Series A+ Led by Grand View Capital to Advance Oligonucleotide Pipeline

Fineline Cube Aug 31, 2026
Company Drug PIC

Eli Lilly Wins FDA Approval for Mounjaro Cardiovascular Risk Reduction in Type 2 Diabetes

Fineline Cube Aug 31, 2026
Company Deals Medical Device PIC

Johnson & Johnson MedTech and CED Medical Sign Third Strategic Cooperation Agreement to Expand Neurointerventional Partnership Behind Qiangyida Stent

Fineline Cube Sep 1, 2026
Policy / Regulatory

NMPA CDE Issues Draft Guideline to Reduce or Replace Animal Testing for Monoclonal Antibodies, Opening Public Comment

Fineline Cube Sep 1, 2026
Company Policy / Regulatory

Shanghai RAAS’s SR604 Enters NMPA CDE Rare Disease Encouragement Program for Hemophilia and Factor VII Deficiency Treatment

Fineline Cube Sep 1, 2026
Company Drug

Luye Pharma’s Once-Weekly Parkinson’s Disease Treatment Receives NMPA Approval

Fineline Cube Jun 21, 2024

Luye Pharma Group (HKG: 2186) has announced that it has received marketing approval from the...

Company Drug

Fudan-Zhangjiang Bio-Pharmaceutical Advances Aminolevulinic Acid Study for Glioma Visualization

Fineline Cube Jun 21, 2024

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd (HKG: 1349; SHA: 688505) has announced that the first subject...

Company Deals

Novartis Moves Toward Full Ownership of MorphoSys with Shareholder Squeeze-Out

Fineline Cube Jun 21, 2024

Novartis AG (NYSE: NVS), the Swiss pharmaceutical giant, is proceeding to fully acquire MorphoSys AG...

Policy / Regulatory

China Expands Controlled Substances Catalogue to Include Three Additional Substances

Fineline Cube Jun 20, 2024

The Ministry of Public Security, National Health Commission, and National Medical Products Administration in China...

Company Drug

Dizal Pharmaceutical’s Golidocitinib Wins NMPA Approval for Relapsed/Refractory PTCL

Fineline Cube Jun 20, 2024

Dizal Pharmaceutical Co., Ltd (SHA: 688192), a spin-off from AstraZeneca China established in 2017, has...

Company Deals

Shanghai Fosun Pharmaceutical Sells Stake in Gland Pharma for USD 211 Million

Fineline Cube Jun 20, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced the sale of...

Company

Jiuzhou Pharmaceutical Shuts Down Two Subsidiaries to Streamline Operations

Fineline Cube Jun 20, 2024

Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHA: 603456), a pharmaceutical company based in China, has announced...

Company Drug

Keymed Biosciences’ CM313 Shows Promise in Treating Immune Thrombocytopenia, NEJM Study Says

Fineline Cube Jun 20, 2024

Keymed Biosciences Inc. (HKG: 2162), a biopharmaceutical company based in China, has published results from...

Company Deals

Xencor Reclaims Rights to Plamotamab After Janssen Halts Development

Fineline Cube Jun 20, 2024

Xencor Inc. (NASDAQ: XNCR), a U.S.-based biotechnology company, has announced that Johnson & Johnson (J&J,...

Company Drug

AbbVie’s Skyrizi Secures FDA Approval for Ulcerative Colitis, Expands Treatment Portfolio

Fineline Cube Jun 20, 2024

AbbVie (NYSE: ABBV) has announced that the U.S. Food and Drug Administration (FDA) has approved...

Company Deals

Genrix Biopharmaceutical and Chongqing Pharmaceutical Group Form Strategic Partnership to Boost Market Launch

Fineline Cube Jun 20, 2024

Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443), a biopharmaceutical company based in China, has entered...

Company

AstraZeneca’s Gracell Biotechnologies to Expand Cell Therapy Manufacturing in China

Fineline Cube Jun 20, 2024

Gracell Biotechnologies, a China-based cell therapy specialist owned by AstraZeneca (AZ; NASDAQ: AZN), is reportedly...

Company Drug

NMPA Releases 81st Batch of Reference Drugs for Generic Quality Consistency Evaluation

Fineline Cube Jun 19, 2024

The National Medical Products Administration (NMPA) has released the 81st batch of reference drugs for...

Company Deals

Grifols Completes Sale of 20% Stake in Shanghai RAAS to Haier Group for RMB 12.5 Billion

Fineline Cube Jun 19, 2024

Grifols AS (NASDAQ: GRFS), a Spain-based global leader in the production of blood products, has...

Company Deals

3SBio Secures Long-Term Financing from IFC for Manufacturing and Global Expansion

Fineline Cube Jun 19, 2024

3SBio Inc. (HKG: 1530), a biopharmaceutical company based in China, is slated to receive long-term...

Company Medical Device

Hybribio Ltd Secures NMPA Approval for α-Thalassemia Genotyping Detection Kit

Fineline Cube Jun 19, 2024

Hybribio Ltd (SHE: 300639), a Guangdong-based provider of nucleic acid molecular diagnostic products, has announced...

Company Drug

Kanghong Pharmaceutical’s Lumitin Approved in Myanmar for Neovascular AMD Treatment

Fineline Cube Jun 19, 2024

Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773), a Chinese pharmaceutical company, has announced that...

Company Drug

Suzhou Zelgen’s Recombinant Human Thyroid Stimulating Hormone Accepted for NMPA Review

Fineline Cube Jun 19, 2024

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a biopharmaceutical company based in China, has announced...

Company Deals

Sanofi Partners with Belharra Therapeutics to Tap into Chemoproteomics for Immunology Targets

Fineline Cube Jun 19, 2024

Sanofi (NASDAQ: SNY; EPA: SAN), a major French pharmaceutical company, has formed a collaboration with...

Company Drug

Clover Biopharmaceuticals’ RSV Vaccine Candidate Shows Promising Results in Elderly

Fineline Cube Jun 19, 2024

Clover Biopharmaceuticals Ltd. (HKG: 2197), a biopharmaceutical company based in China, has announced positive preliminary...

Posts pagination

1 … 391 392 393 … 714

Recent updates

  • NMPA CDE Issues Draft Guideline to Reduce or Replace Animal Testing for Monoclonal Antibodies, Opening Public Comment
  • Shanghai RAAS’s SR604 Enters NMPA CDE Rare Disease Encouragement Program for Hemophilia and Factor VII Deficiency Treatment
  • Eisai Launches LEQEMBI IQLIK Subcutaneous Auto-Injector for Early Alzheimer’s Disease in the United States
  • Trump Signs Nine New MFN Drug Pricing Agreements, Expanding Pharma Deals to 26 Companies Covering 89% of Branded Market
  • Laekna Doses First Patient in Phase I Study of LAE118 PI3Kα Inhibitor for Advanced Solid Tumors, Licensed to Vasque Bio for Up to USD 527 Million
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

NMPA CDE Issues Draft Guideline to Reduce or Replace Animal Testing for Monoclonal Antibodies, Opening Public Comment

Company Policy / Regulatory

Shanghai RAAS’s SR604 Enters NMPA CDE Rare Disease Encouragement Program for Hemophilia and Factor VII Deficiency Treatment

Company Drug

Eisai Launches LEQEMBI IQLIK Subcutaneous Auto-Injector for Early Alzheimer’s Disease in the United States

Policy / Regulatory

Trump Signs Nine New MFN Drug Pricing Agreements, Expanding Pharma Deals to 26 Companies Covering 89% of Branded Market

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2026 | Fineline Information & Technology | BlogData by Themeansar.